Combining therapies targeting DNA polymerase epsilon B-subunit, Human TBK1, and Integrin alpha-v beta-8 could disrupt the pro-cancer signalling cascades while simultaneously addressing cervical cancer’s genomic instability and promising enhanced efficacy and reduced drug resistance [6–8, 18, 19]. The gene discussed is TBK1; the disease is cancer.